These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 25397519)

  • 1. Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy.
    Cozzi-Lepri A; Lo Caputo S; Maggiolo F; Antinori A; Ammassari A; Marchetti G; Mastroianni C; Gori A; Di Perri G; Angarano G; Carbone A; Monforte Ad;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19775. PubMed ID: 25397519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy.
    Cozzi-Lepri A; Antinori A; Bonora S; Cingolani A; Cassola G; Angarano G; Vullo V; Mussini C; Gori A; Maggiolo F; Castagna A;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19771. PubMed ID: 25397515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment.
    Sweet D; Song J; Zhong Y; Signorovitch J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19537. PubMed ID: 25394046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes.
    Elzi L; Erb S; Furrer H; Ledergerber B; Cavassini M; Hirschel B; Vernazza P; Bernasconi E; Weber R; Battegay M;
    Arch Intern Med; 2012 Sep; 172(17):1313-21. PubMed ID: 22892835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and safety analysis. GeSida Study 8114.
    Pérez-Hernández IA; Palacios R; Mayorga M; González-Doménech CM; Castaño M; Rivero A; Del Arco A; Lozano F; Santos J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19795. PubMed ID: 25397539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison.
    Taramasso L; Di Biagio A; Maggiolo F; Tavelli A; Lo Caputo S; Bonora S; Zaccarelli M; Caramello P; Costantini A; Viscoli C; d'Arminio Monforte A; Cozzi-Lepri A;
    HIV Med; 2018 May; ():. PubMed ID: 29846042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort.
    Rokx C; Fibriani A; van de Vijver D; Verbon A; Schutten M; Gras L; Rijnders BJ
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19491. PubMed ID: 25394000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
    Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
    J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis.
    Zaccarelli M; Fabbiani M; Pinnetti C; Borghi V; Giannetti A; Sterrantino G; Lorenzini P; Latini A; Loiacono L; Colafigli M; Ammassari A; D'Ettorre G; Plazzi M; Di Giambenedetto S; Antinori A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19802. PubMed ID: 25397546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
    AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
    AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study.
    Neukam K; Espinosa N; Merino D; Rivero-Juárez A; Carrero A; Ríos MJ; Ruiz-Morales J; Gómez-Berrocal A; Téllez F; Díaz-Menéndez M; Collado A; Pérez-Camacho I; Delgado-Fernández M; Vera-Méndez F; Pineda JA
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19631. PubMed ID: 25394135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication.
    Pinnetti C; Lorenzini P; Cozzi-Lepri A; Sandrine O; Tommasi C; Zaccarelli M; Perno CF; Capobianchi MR; Girardi E; Antinori A; Ammassari A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19809. PubMed ID: 25397553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mean cost of a first combination antiretroviral therapy in HIV-infected patients in France, and determinants of expensive drugs prescription.
    Colombie V; Pugliese-Wehrlen S; Deuffic-Burban S; Cuzin L; Pugliese P; Katlama C; Poizot-Martin I; Raffi F; Cabie A; Dellamonica P; Yazdanpanah Y;
    Int J STD AIDS; 2012 Dec; 23(12):865-9. PubMed ID: 23258826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
    Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load.
    Sterrantino G; Zaccarelli M; Prati F; Boschi A; Sighinolfi L; Borghi V
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19774. PubMed ID: 25397518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability is more important than simplicity for treatment durability.
    Trottier B; Machouf N; Huchet E; Lavoie S; Vezina S; Boissonnault M; Charest L; Munoz M; Legault D; Longpré D; Thomas R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19765. PubMed ID: 25397509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010.
    Jarrin I; Hernández-Novoa B; Alejos B; Riera M; Navarro G; Bernardino JI; Rivero M; del Amo J; Moreno S;
    Antivir Ther; 2013; 18(2):161-70. PubMed ID: 22997147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.